MindMed believes tripping could be big business

By Alma Fabiani

Published May 3, 2021 at 09:39 AM

Reading time: 2 minutes

17636

“We help patients unlock the healing power of the mind through Psychedelic Inspired Medicines & Experiential Therapies. Together we can overcome,” reads MindMed’s website. The company is known for discovering, developing, and deploying psychedelic-inspired medicines to improve health, promote wellness, and alleviate suffering in patients. And that’s not all, on Tuesday 27 April, the biotech company went public on the Nasdaq exchange under the ticker “MNMD.” Here’s how MindMed hopes to capture shares of those markets with its alternative, psychedelic offerings.

After its Nasdaq listing debut on Tuesday, MindMed became the latest psychedelic drug developer to use a major US exchange as a pathway to raise money and bring new mental illness and addiction treatments deeper into the mainstream. This listing means the stock now trades on the Nasdaq Capital Market as well as on the NEO Exchange in Canada.

“Shares surged 33 per cent over the counter on Monday ahead of Tuesday’s listing,” reported Investor’s Business Daily. But things didn’t exactly go to plan—in a public market where stocks can do no wrong, MindMed got torched by close, dropping as much as 30 per cent.

That didn’t stop CEO JR Rahn to stay hopeful about the future of the stock listing, who said in a statement that it would “increase our visibility in the marketplace, improve liquidity, broaden and diversify our shareholder base, and ultimately enhance long-term shareholder value.”

And MindMed’s future does seem interesting. The biotech company is working on an array of projects from LSD’s impact on anxiety and ADHD to a compound it calls 18-MC (a non-hallucinogenic synthetic derivative of ibogaine that is in trials for addiction treatment).

And according to an investor deck, industry stats are all good trips to get on. The global antidepressants market is expected to grow colossally in the next few years, from anxiety and ADHD drugs to depression and anti-addiction treatments.

Like many other psychedelic drug companies, none of MindMed’s major projects has generated revenue or profit yet. In a March filing, the company said it expects operating losses to continue and that it expects to incur “significant costs associated with its research and development initiatives.”

It makes sense then that it is looking for opportunities to garner more attention and money. Now, the question is: is the stock a risky buy currently? Although the global psychedelic drugs market has grown significantly in recent years due to an increasing prevalence of mental disorders, depression, and breakthroughs relating to psychedelic drugs, the market still faces considerable risk and uncertainties before it can secure the US’ FDA approvals.

On top of that, the stigma associated with the use of psychedelic drugs is also a big burden. As of now, the psychedelic drugs market remains at an early developmental stage, with most companies still executing clinical trials. This could hinder MindMed’s growth in the near term. “Although its pipeline projects look promising, there remains high uncertainty regarding its commercial prospects and value,” writes Entrepreneur.

The stock soared 773.9 per cent over the past year, mainly because of a surge in the popularity of psychedelic drugs. That being said, uncertainties regarding a timeline for potential FDA approval of its therapies could mean danger ahead. That’s why it would be wise to avoid the stock and simply enjoy psychedelics as a recreational drug for now. Looks like MindMed is about to go on a bad trip…

Keep On Reading

By Emma O'Regan-Reidy

The cozy gaming trend is empowering women to dominate space in a male-centred industry

By Charlie Sawyer

How Netflix’s Adolescence and Kyle Clifford’s triple murders connect to Andrew Tate

By Fatou Ferraro Mboup

Why do Gen Zers think KFC is using human meat? Unpacking the controversy behind the chain’s latest ad

By Charlie Sawyer

Jenna Ortega’s 2025 film Death of a Unicorn: plot, cast, and everything we know so far

By J'Nae Phillips

The gyaru revival: Why Gen Z are embracing Japan’s most rebellious aesthetic

By Fatou Ferraro Mboup

Latino boycott of Coca-Cola goes viral after TikTok claims the company reported workers to ICE

By Charlie Sawyer

Disturbing signs reading HELP in Los Angeles go viral on X. What do we know so far?

By Charlie Sawyer

TV show hot take: HBO’s Girls is for those in their early 20s, Broad City is for women in their late 20s

By Fatou Ferraro Mboup

Is democracy for sale? How Donald Trump plans to use election betting to declare early victory

By Charlie Sawyer

Can Drake actually sue Kendrick Lamar for his Super Bowl performance diss?

By Louis Shankar

2025’s most anticipated movies: What to watch for in the new year

By Abby Amoakuh

First ever porn app launches on iOS devices to coincide with iPhone’s 18th birthday

By Abby Amoakuh

Epstein and Prince Andrew accuser Virginia Giuffre becomes centre of conspiracy theories after revealing she has days to live

By Fatou Ferraro Mboup

Australian erotic novelist charged with child abuse material offenses after backlash over latest book

By Fatou Ferraro Mboup

Logan Paul trolling the BBC with a lookalike amid cryptocurrency scandal is so on brand

By Fatou Ferraro Mboup

Can you copyright an aesthetic? Two influencers go to court over clean girl trend

By Abby Amoakuh

Anti-ageing obsessed millionaire Bryan Johnson gets backlash for comparing erections to his son’s

By Charlie Sawyer

First Kim Kardashian, now Bianca Censori: How Kanye West uses fashion to subjugate the women in his life

By Charlie Sawyer

From performing at Mother Teresa’s canonization to 10+ film roles, no one works as hard as Rita Ora’s agent

By Abby Amoakuh

A lawyer breaks down Blake Lively and Justin Baldoni’s legal battles. Here’s the verdict